These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17696807)

  • 1. CNS pharmacokinetics of antifungal agents.
    Kethireddy S; Andes D
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):573-81. PubMed ID: 17696807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
    Jullien V
    Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of voriconazole in the treatment of central nervous system blastomycosis.
    Ta M; Flowers SA; Rogers PD
    Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits.
    Clemons KV; Sobel RA; Williams PL; Stevens DA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):612-5. PubMed ID: 11158765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of antifungals.
    Andes D
    Infect Dis Clin North Am; 2006 Sep; 20(3):679-97. PubMed ID: 16984875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds.
    Andes D
    Curr Opin Investig Drugs; 2003 Aug; 4(8):991-8. PubMed ID: 14508883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system.
    Stott KE; Hope W
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):803-815. PubMed ID: 29943650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral aspergillosis: tissue penetration is the key.
    Schwartz S; Thiel E
    Med Mycol; 2009; 47 Suppl 1():S387-93. PubMed ID: 19255905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal pharmacokinetics and pharmacodynamics.
    Lepak AJ; Andes DR
    Cold Spring Harb Perspect Med; 2014 Nov; 5(5):a019653. PubMed ID: 25384765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New dosing strategies for liposomal amphotericin B in high-risk patients.
    Ellis M
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():55-64. PubMed ID: 18430130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.
    Reinwald M; Uharek L; Lampe D; Grobosch T; Thiel E; Schwartz S
    Bone Marrow Transplant; 2009 Aug; 44(4):269-70. PubMed ID: 19219077
    [No Abstract]   [Full Text] [Related]  

  • 13. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance.
    Andes D
    Drug Resist Updat; 2004 Jun; 7(3):185-94. PubMed ID: 15296860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
    Hope WW; Warn PA; Sharp A; Reed P; Keevil B; Louie A; Walsh TJ; Denning DW; Drusano GL
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3760-2. PubMed ID: 17682101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
    Gumbo T
    Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal serum concentration monitoring: an update.
    Goodwin ML; Drew RH
    J Antimicrob Chemother; 2008 Jan; 61(1):17-25. PubMed ID: 17999982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida endophthalmitis: focus on current and future antifungal treatment options.
    Khan FA; Slain D; Khakoo RA
    Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.
    Monforte V; Ussetti P; López R; Gavaldà J; Bravo C; de Pablo A; Pou L; Pahissa A; Morell F; Román A
    J Heart Lung Transplant; 2009 Feb; 28(2):170-5. PubMed ID: 19201343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.
    Walsh TJ; Lester-McCully C; Rinaldi MG; Wallace JE; Balis FM; Lee JW; Pizzo PA; Poplack DG
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1281-4. PubMed ID: 2393291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.